I’m proud to be part of Foundation Medicine as we adopt new clinical technology that benefits patients. We're introducing the next generation of liquid biopsy through our unique clinical measure that can deliver more definitive, clinically actionable results. bit.ly/3sVXpyz

Looking forward to joining the Developing Diagnostics for Personalized Medicine panel at the Personalized Medicine Coalition conference later this week. You can still register here: personalizedmedicineconference.org

I was grateful for the opportunity to talk about the exciting future of cancer monitoring at the @atlanticlive’ People v. Cancer event today. Thank you to Candace Montgomery and The Atlantic for a wonderful conversation! #peoplevcancer

Excited to join @atlanticlive in NYC for the People v. Cancer event on Thursday. You can still register to watch virtually or attend in-person here: bit.ly/3QEifM4

Proud to continue our longstanding commitment to making progress in cancer care through partnership.

WATCH: Matthew A. Powell, MD, discusses the recommended biomarker testing for patients with endometrial cancer and the frontline options available in dMMR/MSI-H endometrial cancer. #gyncsm | Washington U. Med

targetedonc.com/view/recommend…

Great conversation with Deanna van Gestel about increasing opportunities for women in oncology.

At #ESMO23 , we will present #results from the CUPISCO #study , a randomized #PrecisionOncology study designed to prospectively assess the efficacy & safety of molecularly-guided therapy for patients w/ unfavorable subset cancer of unknown primary. More: bit.ly/3M6KUGI

Breast cancer is the 2nd leading cause of cancer death in women. Screening can find  #BreastCancer  early when it is easier to treat. If you have trouble paying for a mammogram, CDC offers free and low-cost screenings to women who qualify.  cdc.gov/cancer/nbccedp…

This week, at #ESMO23 , we’re presenting 11 new studies demonstrating the value of high-quality biomarker tests to inform cancer care. Click the 🔗 to learn more about our research: bit.ly/492V3yj

Amazing strides have been made in cancer research over the last decade, and we still have so much left to learn to help more patients. #BreastCancerAwarenessMonth

We are thrilled to announced that following a successful early access program involving a small group of clinical customers earlier this year, FoundationOne Tracker is now available to all U.S. healthcare providers for treatment response monitoring.

Another important approval to help identify patients with RET gene fusions in any solid tumor who may benefit from treatment with a targeted therapy.

Great new blog from our Chief Commercial Officer Annie Murphy exploring the coverage landscape for comprehensive genomic profiling, and how Foundation Medicine is working to improve patient access to these tests.

Feeling very proud to work at company that not only positively impacts patient care, but also allows employees to grow and feel connected to each other and our mission. #WeAreFMI

Thank you, Shani, for sharing your story of how biomarker testing impacted your husband’s care.

We're excited to share this announcement on our partnership with Roche France & Gustave Roussy to provide in-house liquid biopsy testing for cancer patients in France. Read the full press release here: bit.ly/3EKvrbu

Great interview with Dr. Julie Gralow about pushing the boundaries and not accepting the status quo in order to make progress for patients.

#ResearchSpotlight - study analyzed the genomic landscape, comprehensive genomic profiling utilization & treatment patterns across a diverse cohort of patients with advanced #ProstateCancer to assess ancestry-based disparities. Click here to read more: bit.ly/3OOD4Ub

Honoring and recognizing all who have had or are living with childhood, blood, ovarian and prostate cancers this September.